Compound: Norverapamil
SMILES: O(c1c(OC)ccc(c1)C(C#N)(C(C)C)CCCNCCc2cc(OC)c(OC)cc2)C
InChIKey: UPKQNCPKPOLASS-UHFFFAOYSA-N
Synonyms: Norverapamil, 67018-85-3, DTXSID80873799, 957Z3K3R56, 2-(3,4-dimethoxyphenyl)-5-[2-(3,4-dimethoxyphenyl)ethylamino]-2-propan-2-ylpentanenitrile, alpha-(3-((2-(3,4-Dimethoxyphenyl)ethyl)amino)propyl)-3,4-dimethoxy-alpha-(1-methylethyl)benzeneacetonitrile, D-591, N-demethylverapamil, Benzeneacetonitrile, alpha-(3-((2-(3,4-dimethoxyphenyl)ethyl)amino)propyl)-3,4-dimethoxy-alpha-(1-methylethyl)-, 2-(3,4-dimethoxyphenyl)-5-(2-(3,4-dimethoxyphenyl)ethylamino)-2-propan-2-ylpentanenitrile, (2RS)-2-(3,4-Dimethoxyphenyl)-5-((2-(3,4-dimethoxy-phenyl)ethyl)amino)-2-(1-methylethyl)pentanenitrile, RefChem:854768, CHEBI:132050, DTXCID701012017, 266-544-8, Verapamil EP Impurity J, NORVERAPAMIL (6%), CHEMBL1298, 5-((3,4-dimethoxyphenethyl)amino)-2-(3,4-dimethoxyphenyl)-2-isopropylpentanenitrile, 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl]amino}-2-(propan-2-yl)pentanenitrile, (+/-)-Norverapamil;D591, Benzeneacetonitrile, .alpha.-[3-[[2-(3,4-dimethoxyphenyl)ethyl]amino]propyl]-3,4-dimethoxy-.alpha.-(1-methylethyl)-, EINECS 266-544-8, Verapamil-M nor, UNII-957Z3K3R56, Nor-R-Verapamil, BENZENEACETONITRILE, .ALPHA.-(3-((2-(3,4-DIMETHOXYPHENYL)ETHYL)AMINO)PROPYL)-3,4-DIMETHOXY-.ALPHA.-(1-METHYLETHYL)-, N-NORVERAPAMIL, ()-Norverapamil;D591, (+/-)-NORVERAPAMIL, NORVERAPAMIL [WHO-DD], SCHEMBL222066, orb1709015, SCHEMBL15837507, SCHEMBL29800999, CHEBI:134080, BDBM50121977, NSC672815, AKOS015962103, NSC-672815, 5-((3,4-Dimethoxyphenethyl)amino)-2-(3,4-dimethoxyphenyl)-2-isopropylvaleronitrile, NCGC00168468-01, AC-15973, DA-66192, HY-135328, CS-0111432, NS00004446, Q7060761, VERAPAMIL HYDROCHLORIDE IMPURITY J [EP IMPURITY], 2-(3,4-dimethoxyphenyl)-5-[2-(3,4-dimethoxyphenyl)ethylamino]-2-isopropyl-pentanenitrile, 2-(3,4-Dimethoxy-phenyl)-5-[2-(3,4-dimethoxy-phenyl)-ethylamino]-2-isopropyl-pentanenitrile, 2-(3,4-Dimethoxyphenyl)-5-([2-(3,4-dimethoxyphenyl)ethyl]amino)-2-isopropylpentanenitrile #
Theoretical properties:
molecular_formula: C26H36N2O4
molecular_weight: 440.6 g/mol
exact_mass: 440.26750763 g/mol
formal_charge: 0
hydrogen_bond_donor_count: 1
hydrogen_bond_acceptor_count: 6
rotatable_bond_count: 13
heavy_atom_count: 32
topological_polar_surface_area: 72.7 Å²
isotope_atom_count: 0
covalently_bonded_unit_count: 1
Physical properties:
Descriptions:
pubchem: 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl]amino}-2-(propan-2-yl)pentanenitrile is a secondary amino compound that is 3,4-dimethoxyphenylethylamine in which one of the hydrogens attached to the nitrogen has been replaced by a 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl group. It is a nitrile, an aromatic ether, a polyether and a secondary amino compound.
chebi: A secondary amino compound that is 3,4-dimethoxyphenylethylamine in which one of the hydrogens attached to the nitrogen has been replaced by a 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl group.
chembl: NORVERAPAMIL is a small molecule listed in the ChEMBL database but has not progressed to an approved clinical phase.
wikipedia: Norverapamil is a calcium channel blocker. It is the main active metabolite of verapamil. It contributes significantly to the therapeutic effects of verapamil, which include the treatment of hypertension, angina, and arrhythmias. Despite being a metabolite of verapamil, norverapamil retains much of the pharmacological activity of verapamil, particularly impacting the calcium ion flow through L-type calcium channels, leading to its therapeutic cardiovascular and vasodilation effects.